BioSpace News Archive

Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to provide an update on its commercial strategy to bring innovative therapies to patients suffering from chemotherapy induced nausea and vomiting (CINV)

Carmell Therapeutics, a pioneering company in the development and commercialization of innovative Plasma-based Bioactive Materials (PBMs) to accelerate bone and soft tissue healing, today announced that Dr. Israel Nur joined the company as a Scientific Advisor

Resonant Inc. (NASDAQ: RESN), a leader in transforming the way radio frequency, or RF, front-ends are being designed and delivered for mobile handsets and wireless devices, has provided preliminary unaudited financial and operational results for the three months ended September 30, 2020.

Eli Lilly and Company (NYSE: LLY) today announced additional details on its SARS-CoV-2 neutralizing antibody programs – including interim data on combination therapy in recently diagnosed patients with mild-to-moderate COVID-19 – and plans to make these therapies broadly available to patients.

Ambu Inc., the world leader in single-use endoscopes, announced that it has been awarded a national single-use endoscopy contract in the category of Single-Use Endoscopes with a major U.S. Group Purchasing Organization.

Propella Therapeutics Inc. (Propella), a leader in the development of innovative best-in-class prescription products, today announced the issuance of a U.S. patent for a new drug treatment for metastatic prostate cancer.

The effects of screens on children’s sleep have been a focus of public health concern for decades.

Renibus Therapeutics, Inc., a clinical-stage biotechnology company, announced today that its investigational treatment for COVID-19, RBT-9, has demonstrated antiviral activity in vitro against SARS-CoV-2, the virus that causes COVID-19. RBT-9 initially showcased broad antiviral activity against several enveloped viruses – as well as protective effects for vital organs, including the lungs, heart, kidneys and liver. Laboratory studies performed

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the FDA has granted Orphan Drug Designation (“ODD”) and Rare Pediatric Disease Designation (“RPDD”) for its leading bispecific antibody program nivatrotamab for the treatment of neuroblastoma.

NC-iMSCs demonstrate higher potency, uniformity and consistency - significant advantages over donor derived MSCs